Hemostasis parameters in patients with COVID-19 on admission
| . | Patients (n = 30) . | Healthy individuals (n = 30) . | P* . |
|---|---|---|---|
| Fibrinogen, mg/dL | 773.7 (696.8-913.1) | 325.0 (283.4-343.4) | <.001 |
| PT, s | 11.8 (11.4-12.7) | 11.1 (10.7-11.1) | .15 |
| aPTT, s | 33.7 ± 5.1 | 30.75 ± 2.4 | .01 |
| FVIII activity, % | 219.9 ± 93.3 | 132.1 ± 31.3 | <.001 |
| FIX activity, % | 179.6 ± 47.1 | 119.0 ± 24.9 | <.001 |
| FX activity, % | 127.7 ± 25.8 | 112.9 ± 19.3 | .02 |
| FXI activity, % | 192.9 ± 48.4 | 124.9 ± 29.3 | <.001 |
| FXII activity, % | 214.5 ± 80.9 | 174.1 ± 47.1 | .03 |
| VWF:Ag, IU/dL | 248.0 (238.2-475.8) | 162.3 (95.3-189.5) | <.001 |
| Ristocetin cofactor activity, % | 311.7 ± 66.4 | 130.5 ± 44.9 | <.001 |
| VWF:Ag/FVIII ratio | 1.34 (1.04-2.15) | 1.15 (0.94-1.27) | .001 |
| P-selectin, pg/mL | 3540.5 ± 1773.8 | 2926 ± 1352.7 | .14 |
| AT, % | 114.1 ± 17.9 | 109.4 ± 10.5 | .26 |
| uPAR, ng/mL | 1.80 ± 0.57 | 1.08 ± 0.30 | <.001 |
| PAI-1, pg/mL | 702.1 ± 153.3 | 588.4 ± 194.7 | .015 |
| PAP, μg/mL | 1.24 (0.99-2.10) | 0.35 (0.30-0.46) | <.001 |
| . | Patients (n = 30) . | Healthy individuals (n = 30) . | P* . |
|---|---|---|---|
| Fibrinogen, mg/dL | 773.7 (696.8-913.1) | 325.0 (283.4-343.4) | <.001 |
| PT, s | 11.8 (11.4-12.7) | 11.1 (10.7-11.1) | .15 |
| aPTT, s | 33.7 ± 5.1 | 30.75 ± 2.4 | .01 |
| FVIII activity, % | 219.9 ± 93.3 | 132.1 ± 31.3 | <.001 |
| FIX activity, % | 179.6 ± 47.1 | 119.0 ± 24.9 | <.001 |
| FX activity, % | 127.7 ± 25.8 | 112.9 ± 19.3 | .02 |
| FXI activity, % | 192.9 ± 48.4 | 124.9 ± 29.3 | <.001 |
| FXII activity, % | 214.5 ± 80.9 | 174.1 ± 47.1 | .03 |
| VWF:Ag, IU/dL | 248.0 (238.2-475.8) | 162.3 (95.3-189.5) | <.001 |
| Ristocetin cofactor activity, % | 311.7 ± 66.4 | 130.5 ± 44.9 | <.001 |
| VWF:Ag/FVIII ratio | 1.34 (1.04-2.15) | 1.15 (0.94-1.27) | .001 |
| P-selectin, pg/mL | 3540.5 ± 1773.8 | 2926 ± 1352.7 | .14 |
| AT, % | 114.1 ± 17.9 | 109.4 ± 10.5 | .26 |
| uPAR, ng/mL | 1.80 ± 0.57 | 1.08 ± 0.30 | <.001 |
| PAI-1, pg/mL | 702.1 ± 153.3 | 588.4 ± 194.7 | .015 |
| PAP, μg/mL | 1.24 (0.99-2.10) | 0.35 (0.30-0.46) | <.001 |
Data are given as median (interquartile range) or mean ± standard deviation. Two sodium citrate samples from patients were not processed because of critical preanalytic issues (low volume).
Ag, antigen; aPTT, activated partial thromboplastin time; PAP, plasmin-antiplasmin complexes; PT, prothrombin time; uPAR, urokinase-type plasminogen activator receptor; VWF, von Willebrand factor.
Mann-Whitney or t test for nonparametric or parametric data, respectively.